Advertisement

Clinical and Experimental Medicine

, Volume 12, Issue 3, pp 173–180 | Cite as

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

  • Yefei Rong
  • Xia Qin
  • Dayong Jin
  • Wenhui Lou
  • Lili Wu
  • Dansong Wang
  • Wenchuan Wu
  • Xiaolin Ni
  • Zhengfa Mao
  • Tiantao Kuang
  • Ying Qin ZangEmail author
  • Xinyu QinEmail author
Original Article

Abstract

The objectives of this study were to assess the toxicity and immunological response induced by the intra-dermal (i.d.) administration of MUC1-peptide-pulsed dendritic cells (DCs) in advanced pancreatic cancer patients. Patients with recurrent lesions or metastasis after surgery, and immunohistochemistry positive for MUC1 were treated in cohorts that received 3–6 × 106 DCs i.d. for three or four vaccines. Each vaccine was composed of autologus DCs pulsed with MUC1-peptide. Peripheral blood mononuclear cells (PBMCs) that harvested 2 weeks after the second immunization were compared with PBMCs obtained before treatment for immunological response. Serial ELISPOT assays of PBMCs for antitumor reactivity were performed. Three patients received all four vaccines, and four patients received three vaccines. These patients were evaluable for toxicity and immunological monitoring. There were no grade 3 or 4 toxicities associated with the vaccines or major evidence of autoimmunity. Interferon-γ and granzyme B ELISPOT assay reactivity increased significantly in 2 of 7 patients (P < 0.05). The administration of MUC1-peptide-pulsed DCs is non-toxic and capable of inducing immunological response to tumor antigen MUC1 in advanced pancreatic cancer patients. Additional studies are necessary to improve tumor rejection responses.

Keywords

Dendritic cell MUC1 Immunotherapy Pancreatic cancer 

Notes

Acknowledgments

This study was supported by the Key basic Grant in Biological Medicine (No.06DZ19009) from Shanghai, China and the Youth Grant (S-61) from the Fudan Univesity, Shanghai, China. We thank the pathologists in our hospital for skillful technical assistance, and we thank the haematologits for their help in collecting PBMCs.

Conflict of interest

None.

References

  1. 1.
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics. CA Cancer J Clin 55(1):10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Ries L, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Mariotto A, Feuer EJ, Edwards BK (2006) SEER cancer statistics review, 1975–2003. Bethesda. National Cancer Institute, MDGoogle Scholar
  3. 3.
    Takhar AS, Palaniappan P, Dhingsa R, Lobo DN (2004) Recent developments in diagnosis of pancreatic cancer. BMJ 329(7467):668–673PubMedCrossRefGoogle Scholar
  4. 4.
    Donghui L, Keping X, Robert W, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363(9414):1049–1057CrossRefGoogle Scholar
  5. 5.
    Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushai S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas -616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567–579PubMedCrossRefGoogle Scholar
  6. 6.
    Abrams RA (2003) Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? Int J Radiat Oncol Biol Phys 56(Suppl 4):3–9PubMedCrossRefGoogle Scholar
  7. 7.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Berger H, Fernandez-Cruz L, Dervenis C, Lacaine F et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210PubMedCrossRefGoogle Scholar
  8. 8.
    Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54(11):2856–2860PubMedGoogle Scholar
  9. 9.
    Pierre G, Jenny V, Laurence Z, Théry C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621–667CrossRefGoogle Scholar
  10. 10.
    Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475–480PubMedCrossRefGoogle Scholar
  11. 11.
    Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24(1):66–78PubMedCrossRefGoogle Scholar
  12. 12.
    Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN (2008) Pilot study of mutant Ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 57(9):1413–1420PubMedCrossRefGoogle Scholar
  13. 13.
    Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ (2002) A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8(4):1021–1032PubMedGoogle Scholar
  14. 14.
    Pecher G, Häring A, Kaiser L, Thiel E (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51(11–12):669–673PubMedCrossRefGoogle Scholar
  15. 15.
    Jacques B, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5(4):296–306CrossRefGoogle Scholar
  16. 16.
    Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99(2):931–936PubMedCrossRefGoogle Scholar
  17. 17.
    Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45–60PubMedCrossRefGoogle Scholar
  18. 18.
    Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V et al (2006) Mannan-MUC1 pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12(3):869–877PubMedCrossRefGoogle Scholar
  19. 19.
    Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59(1):56–58PubMedGoogle Scholar
  20. 20.
    Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ (2001) Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61(2):641–646PubMedGoogle Scholar
  21. 21.
    Fong L, Brockstedt D, Benike C, Wu L, Engleman EG (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166(6):4254–4259PubMedGoogle Scholar
  22. 22.
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328–332PubMedCrossRefGoogle Scholar
  23. 23.
    Lawrence F, Edgar GE (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245–273CrossRefGoogle Scholar
  24. 24.
    Barth RJ, Mule JJ, Spiess PJ, Rosenberg SA (1991) Interferon γ and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173(3):647–658PubMedCrossRefGoogle Scholar
  25. 25.
    Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ (1998) Successful adoptive cellular immuno-therapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J Immunol 160(1):334–344PubMedGoogle Scholar
  26. 26.
    Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ (1994) Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76(6):977–987PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Yefei Rong
    • 1
  • Xia Qin
    • 2
  • Dayong Jin
    • 1
  • Wenhui Lou
    • 1
  • Lili Wu
    • 2
  • Dansong Wang
    • 1
  • Wenchuan Wu
    • 1
  • Xiaolin Ni
    • 1
  • Zhengfa Mao
    • 1
  • Tiantao Kuang
    • 1
  • Ying Qin Zang
    • 3
    Email author
  • Xinyu Qin
    • 1
    Email author
  1. 1.Pancreatic Cancer Group, General Surgery Department, Zhongshan HospitalFudan UniversityShanghaiChina
  2. 2.Biotherapy Center, Institute of Immunology, the School of MedicineJiaotong UniversityShanghaiChina
  3. 3.Institute for Nutritional Sciences, Shanghai Institutes of Biological ScienceChinese Academy of SciencesShanghaiChina

Personalised recommendations